Welcome to Molecular Oncology Tumor Boards

The Molecular Oncology Tumor Boards are a series of bi-monthly, user-driven discussions designed to help cancer care providers with the interpretation and understanding of tumor molecular profiling tests and studies. Moderated by an expert pathologist and medical oncologist, each case will be updated with new information over a 2-week period as user comments are added. Sign in with your ASCO username and password to participate. After 2 weeks, the discussion will be locked to further commentary and users will be able to claim CME credit for their participation. Visit ASCO University to learn more. 

To participate in discussions on other oncology-related topics, visit ASCO’s member community on myConnection. Connect with colleagues, build your professional network, exchange ideas, collaborate, and more

LOGIN TO START A DISCUSSION
Molecular Oncology Tumor Board
ASCO University
Feb 15, 2017 8:30 AM
Read more to answer the following questions:
1.    Recognize the diagnosis of CML and importance of bone marrow biopsy at presentation.
2.    Apply considerations when choosing initial therapy.
3.    Recognize when to switch therapy when response is suboptimal.
4.    Identify how to treat...
Molecular Oncology Tumor Board
ASCO University
Jan 11, 2017 2:00 PM
Read more to answer the following questions: 1) Which tests are the most appropriate in identifying a BRAF codon 600 mutation for potential FDA-targeted treatment? 2) What is the significance of the CDKN2A mutation? 3) If systemic therapy is selected, would you be more inclined to offer targeted...
Molecular Oncology Tumor Board
ASCO University
Dec 07, 2016 8:16 AM
Read more to answer the following questions:
Is further tissue needed to confirm radiologically presumed metastatic disease or for repeat HER2 testing? What systemic therapy option would you recommend for confirmed HER2 negative metastatic gastric cancer?
Molecular Oncology Tumor Board
ASCO University
Nov 09, 2016 11:09 AM
Read more to answer the following questions:

 Recognize the clinical characteristics and outcomes for patients with FLT3 mutations?
Describe the role of FLT3 inhibitors for the initial treatment of AML?
Understand the role of gene mutations, including CLT3,  in the pathologic classification of...
Molecular Oncology Tumor Board
ASCO University
Oct 12, 2016 9:33 AM
Read more to answer the following questions: Who should get routine molecular testing at diagnosis for NSCLC and what tests should be performed? What is the most appropriate initial treatment for this patient?

Pages


Advertisement